ABSTRACT
The Epstein-Barr Virus (EBV) is involved in the etiology of multiple hematologic and epithelial human cancers. EBV+ tumors employ multiple immune escape mechanisms, including the recruitment of immunosuppressive regulatory T cells (Treg). Here, we show some EBV+ tumor cells express high levels of the chemokines CCL17 and CCL22 both in vitro and in vivo and that this expression mirrors the expression levels of expression of the EBV LMP1 gene in vitro. Patient samples from lymphoblastic (Hodgkin lymphoma) and epithelial (nasopharyngeal carcinoma; NPC) EBV+ tumors revealed CCL17 and CCL22 expression of both tumor cell-intrinsic and -extrinsic origin, depending on tumor type. NPCs grown as mouse xenografts likewise showed both mechanisms of chemokine production. Single cell RNA-sequencing revealed in vivo tumor cell-intrinsic CCL17 and CCL22 expression combined with expression from infiltrating classical resident and migratory dendritic cells in a CT26 colon cancer mouse tumor engineered to express LMP1. These data suggest that EBV-driven tumors employ dual mechanisms for CCL17 and CCL22 production. Importantly, both in vitro and in vivo Treg migration was effectively blocked by a novel, small molecule antagonist of CCR4, CCR4-351. Antagonism of the CCR4 receptor may thus be an effective means of activating the immune response against a wide spectrum of EBV+ tumors.
Subject(s)
Chemokine CCL17/immunology , Chemokine CCL22/immunology , Epstein-Barr Virus Infections/immunology , Neoplasms/immunology , Neoplasms/virology , T-Lymphocytes, Regulatory/immunology , Animals , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human , Heterografts , Hodgkin Disease/immunology , Hodgkin Disease/virology , Humans , Mice , Nasopharyngeal Carcinoma/immunology , Nasopharyngeal Carcinoma/virology , Nasopharyngeal Neoplasms/immunology , Nasopharyngeal Neoplasms/virologyABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by an impaired skin barrier and intense itchiness, which decreases the individual's quality of life. No fully effective therapeutic agents have prevailed for AD due to an insufficient grasp of the complex etiology. Ellagic acid (EA), a natural compound, has anti-inflammatory properties in chronic diseases. The effects of EA on AD have not yet been explored. The present study investigated the effects of EA on TNF-α/IFN-γ-stimulated HaCaT keratinocytes and house dust mite-induced AD-like skin lesions in NC/Nga mice. Treatment with EA suppressed inflammatory responses in keratinocytes by regulating critical inflammatory signaling pathways, such as mitogen-activated protein kinases and signal transducers and activators of transcription. In vivo studies using a DfE-induced AD mouse model showed the effects of EA administration through ameliorated skin lesions via decremented histological inflammatory reactions. These results suggest that EA could be a potential therapeutic alternative for the treatment of AD by inhibiting inflammatory signaling pathways.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Dermatitis, Atopic/drug therapy , Dermatophagoides farinae/chemistry , Ellagic Acid/pharmacology , Mitogen-Activated Protein Kinases/genetics , STAT1 Transcription Factor/genetics , STAT3 Transcription Factor/genetics , Animals , Antigens, Dermatophagoides/administration & dosage , Chemokine CCL17/genetics , Chemokine CCL17/immunology , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Chemokine CCL5/genetics , Chemokine CCL5/immunology , Complex Mixtures/administration & dosage , Cytokines/genetics , Cytokines/immunology , Dermatitis, Atopic/chemically induced , Dermatitis, Atopic/genetics , Dermatitis, Atopic/immunology , Dermatophagoides farinae/immunology , Disease Models, Animal , Female , Gene Expression Regulation , HaCaT Cells , Humans , Interferon-gamma/antagonists & inhibitors , Interferon-gamma/pharmacology , Mice , Mitogen-Activated Protein Kinases/immunology , STAT1 Transcription Factor/immunology , STAT3 Transcription Factor/immunology , Signal Transduction , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/pharmacology , Thymic Stromal LymphopoietinABSTRACT
CCL22 is a key mediator of leukocyte trafficking in inflammatory immune responses, allergy, and cancer. It acts by attracting regulatory T cells and Th2 cells via their receptor CCR type 4 (CCR4). Beyond its role in inflammation, CCL22 is constitutively expressed at high levels in lymphoid organs during homeostasis, where it controls immunity by recruiting regulatory T cells to dendritic cells (DCs). In this study, we aimed to identify the mechanisms responsible for constitutive CCL22 expression. We confirmed that CD11c+ DCs are the exclusive producers of CCL22 in secondary lymphatic organs during homeostasis. We show that in vitro both murine splenocytes and human PBMCs secrete CCL22 spontaneously without any further stimulation. Interestingly, isolated DCs alone, however, are unable to produce CCL22, but instead require T cell help. In vitro, only the coculture of DCs with T cells or their supernatants resulted in CCL22 secretion, and we identified T cell-derived GM-CSF as the major inducer of DC-derived CCL22 expression. In vivo, Rag1 -/- mice, which lack functional T cells, have low CCL22 levels in lymphoid organs, and this can be restored by adoptive transfer of wild-type T cells or administration of GM-CSF. Taken together, we uncover T cell-derived GM-CSF as a key inducer of the chemokine CCL22 and thus, to our knowledge, identify a novel role for this cytokine as a central regulator of immunity in lymphatic organs. This knowledge could contribute to the development of new therapeutic interventions in cancer and autoimmunity.
Subject(s)
Chemokine CCL22/immunology , Dendritic Cells/immunology , Gene Expression Regulation/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , T-Lymphocytes, Regulatory/immunology , Animals , CD11 Antigens/genetics , CD11 Antigens/immunology , Chemokine CCL22/genetics , Dendritic Cells/cytology , Gonadotropin-Releasing Hormone/analogs & derivatives , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Mice, Knockout , T-Lymphocytes, Regulatory/cytology , Th2 Cells/cytology , Th2 Cells/immunologyABSTRACT
Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-based cancer therapies. Here, we report that growth of BRAF-mutant melanoma cells is inhibited, up to complete rejection, in Siah2-/- mice. Growth-inhibited tumors exhibit increased numbers of intra-tumoral activated T cells and decreased expression of Ccl17, Ccl22, and Foxp3. Marked reduction in Treg proliferation and tumor infiltration coincide with G1 arrest in tumor infiltrated Siah2-/- Tregs in vivo or following T cell stimulation in culture, attributed to elevated expression of the cyclin-dependent kinase inhibitor p27, a Siah2 substrate. Growth of anti-PD-1 therapy resistant melanoma is effectively inhibited in Siah2-/- mice subjected to PD-1 blockade, indicating synergy between PD-1 blockade and Siah2 loss. Low SIAH2 and FOXP3 expression is identified in immune responsive human melanoma tumors. Overall, Siah2 regulation of Treg recruitment and cell cycle progression effectively controls melanoma development and Siah2 loss in the host sensitizes melanoma to anti-PD-1 therapy.
Subject(s)
Melanoma/immunology , Nuclear Proteins/immunology , T-Lymphocytes, Regulatory/immunology , Ubiquitin-Protein Ligases/immunology , Animals , Chemokine CCL17/genetics , Chemokine CCL17/immunology , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Forkhead Box Protein O3/genetics , Forkhead Box Protein O3/immunology , Humans , Melanoma/genetics , Mice , Mice, Knockout , Nuclear Proteins/genetics , Ubiquitin-Protein Ligases/geneticsABSTRACT
The heterogeneity and complexity of tumor-immune microenvironments lead to diverse immunotherapy effects among colon cancer patients. It is crucial to identify immune microenvironment-related biomarkers and construct prognostic risk models. In this study, the immune and stromal scores of 415 cases from TCGA were calculated using the ESTIMATE algorithm. AXIN2, CCL22, CLEC10A, CRIP2, RUNX3, and TRPM5 were screened and established a prognostic immune-related gene (IRG) signature using by univariate, LASSO, and multivariate Cox regression models. The predicted performance of IRG signature was external validated by GSE39582 (n=519). Stratified survival analysis showed IRG signature was an effective predictor of survival in patients with different clinical characteristics. The protein expression level of six genes was validated by immunohistochemistry analysis. Difference analysis indicated the mutation rate, immune cell of resting NK cells and regulatory T cells infiltration and four immune checkpoints of PD-1, PD-L1, LAG3 and VSIR expression levels in the high-risk group were significantly higher than those in the low-risk group. A nomogram incorporating the gene signatures and clinical factors was demonstrated had a good accuracy (1-, 3-, and 5-year AUC= 0.799, 0.791, 0.738). Our study identified a novel IRG signature, which may provide some references for the clinical precision immunotherapy of patients.
Subject(s)
Adenocarcinoma/genetics , Colonic Neoplasms/genetics , Transcriptome , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/immunology , Adenocarcinoma/immunology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Aged , Antigens, CD/genetics , Antigens, CD/immunology , Axin Protein/genetics , Axin Protein/immunology , B7 Antigens/genetics , B7 Antigens/immunology , B7-H1 Antigen/genetics , B7-H1 Antigen/immunology , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Colonic Neoplasms/immunology , Colonic Neoplasms/mortality , Colonic Neoplasms/pathology , Core Binding Factor Alpha 3 Subunit/genetics , Core Binding Factor Alpha 3 Subunit/immunology , Databases, Genetic , Female , Humans , Killer Cells, Natural , LIM Domain Proteins/genetics , LIM Domain Proteins/immunology , Lectins, C-Type/genetics , Lectins, C-Type/immunology , Lymphocytes, Tumor-Infiltrating , Male , Middle Aged , Multivariate Analysis , Nomograms , Prognosis , Programmed Cell Death 1 Receptor/genetics , Programmed Cell Death 1 Receptor/immunology , Proportional Hazards Models , Survival Rate , T-Lymphocytes, Regulatory , TRPM Cation Channels/genetics , TRPM Cation Channels/immunology , Tumor Microenvironment/genetics , Tumor Microenvironment/immunology , Lymphocyte Activation Gene 3 ProteinABSTRACT
AIMS: To date, the ROS-generating capacities of macrophages in different activation states have not been thoroughly compared. This study is aimed at determining the nature and levels of ROS generated following stimulation with common activators of M1 and M2 macrophages and investigating the potential for this to impact fibrosis. RESULTS: Human primary and THP-1 macrophages were treated with IFN-γ+LPS or IL-4-activating stimuli, and mRNA expression of established M1 (CXCL11, CCR7, IL-1ß) and M2 (MRC-1, CCL18, CCL22) markers was used to confirm activation. Superoxide generation was assessed by L-012-enhanced chemiluminescence and was increased in both M(IFN-γ+LPS) and M(IL-4) macrophages, as compared to unpolarised macrophages (MΦ). This signal was attenuated with NOX2 siRNA. Increased expression of the p47phox and p67phox subunits of the NOX2 oxidase complex was evident in M(IFN-γ+LPS) and M(IL-4) macrophages, respectively. Amplex Red and DCF fluorescence assays detected increased hydrogen peroxide generation following stimulation with IL-4, but not IFN-γ+LPS. Coculture with human aortic adventitial fibroblasts revealed that M(IL-4), but not M(IFN-γ+LPS), enhanced fibroblast collagen 1 protein expression. Macrophage pretreatment with the hydrogen peroxide scavenger, PEG-catalase, attenuated this effect. CONCLUSION: We show that superoxide generation is not only enhanced with stimuli associated with M1 macrophage activation but also with the M2 stimulus IL-4. Macrophages activated with IL-4 also exhibited enhanced hydrogen peroxide generation which in turn increased aortic fibroblast collagen production. Thus, M2 macrophage-derived ROS is identified as a potentially important contributor to aortic fibrosis.
Subject(s)
Fibroblasts/drug effects , Interferon-gamma/pharmacology , Interleukin-4/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/drug effects , Signal Transduction/genetics , Catalase/pharmacology , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Chemokine CXCL11/genetics , Chemokine CXCL11/immunology , Chemokines, CC/genetics , Chemokines, CC/immunology , Coculture Techniques , Collagen Type I/genetics , Collagen Type I/immunology , Fibroblasts/cytology , Fibroblasts/immunology , Gene Expression Regulation , Humans , Hydrogen Peroxide/metabolism , Interferon-gamma/antagonists & inhibitors , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Interleukin-4/antagonists & inhibitors , Lipopolysaccharides/antagonists & inhibitors , Macrophage Activation/drug effects , Macrophages/cytology , Macrophages/immunology , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , NADPH Oxidase 2/genetics , NADPH Oxidase 2/immunology , Oxidation-Reduction/drug effects , Polyethylene Glycols/pharmacology , Primary Cell Culture , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Receptors, CCR7/genetics , Receptors, CCR7/immunology , Receptors, Immunologic/genetics , Receptors, Immunologic/immunology , Superoxides/metabolism , THP-1 CellsABSTRACT
BACKGROUND: Cytokines and chemokines play critical roles in the pathogenesis of asthma. Azithromycin, a macrolides, is frequently used in asthmatic children with lower respiratory tract infection and is reported having anti-inflammatory and immunomodulatory effects. However, the effects of azithromycin on the expression of TNF-α, Th1- and Th2-related chemokines, and neutrophil chemoattractant are unknown. We investigated the in vitro effects of azithromycin on the expression of TNF-α, Th1-related chemokine interferon-γ-inducible protein-10 (IP-10/CXCL10), Th2-related chemokine macrophage-derived chemokine (MDC/CCL22) and neutrophil chemoattractant growth-related oncogene-α (GRO-α/CXCL1) in THP-1 cells as a model for human monocytes. METHODS: THP-1 cells were pretreated with various concentrations of azithromycin before Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) stimulation. TNF-α, IP-10, MDC and GRO-α were measured by ELISA. Intracellular signaling was investigated by pathway inhibitors and Western blot. RESULT: Azithromycin suppressed MDC and IP-10 expression in LPS-stimulated THP-1 cells. However, azithromycin had no effect LPS-induced TNF-α and GRO-α expression. Western blotting revealed that azithromycin suppressed LPS-induced phosphorylation of mitogen-activated protein kinase (MAPK)-JNK and ERK expression, and also suppressed LPS-induced phosphorylation of nuclear factor (NF) κB-p65 expression. CONCLUSION: Azithromycin suppressed LPS-induced MDC expression via the MAPK-JNK and the NFκB-p65 pathway. Azithromycin also suppressed LPS-induced IP-10 via the MAPK-JNK/ERK and the NFκB-p65 pathway. Azithromycin may benefit asthmatic patients by suppressing chemokines expression.
Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Chemokine CCL22/antagonists & inhibitors , Chemokine CXCL10/antagonists & inhibitors , Monocytes/drug effects , Monocytes/immunology , Chemokine CCL22/immunology , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL1/immunology , Chemokine CXCL10/immunology , Enzyme-Linked Immunosorbent Assay , Humans , Lipopolysaccharides , MAP Kinase Signaling System , THP-1 Cells , Th1 Cells/drug effects , Th1 Cells/immunology , Th2 Cells/drug effects , Th2 Cells/immunology , Transcription Factor RelA , Tumor Necrosis Factor-alpha/immunologyABSTRACT
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas associated with chronic inflammation (DLBCL-CI) develop in patients with chronic inflammation but without any predisposing immunodeficiency. Given the expression of the EBV latent genes, DLBCL-CI should have mechanisms for evasion of host antitumor immunity. EBV-positive pyothorax-associated lymphoma (PAL) is a prototype of DLBCL-CI and may provide a valuable model for the study of immune evasion by DLBCL-CI. This study demonstrates that PAL cell lines express and secrete CCL17 and/or CCL22 chemokines, the ligands of C-C motif chemokine receptor 4 (CCR4), in contrast to EBV-negative DLBCL cell lines. Accordingly, culture supernatants of PAL cell lines efficiently attracted CCR4-positive regulatory T (Treg) cells in human peripheral blood mononuclear cells. PAL cells injected into mice also attracted CCR4-expressing Treg cells. Furthermore, this study confirmed that CCR4-expressing Treg cells were abundantly present in primary PAL tissues. Collectively, these findings provide new insight into the mechanisms of immune evasion by PAL, and further studies are warranted on whether such mechanisms eventually lead to the development of DLBCL-CI.
Subject(s)
Chemokine CCL17/biosynthesis , Chemokine CCL22/biosynthesis , Empyema, Pleural/immunology , Epstein-Barr Virus Infections/immunology , Lymphoma, Large B-Cell, Diffuse/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Cell Line, Tumor , Chemokine CCL17/immunology , Chemokine CCL22/immunology , Empyema, Pleural/pathology , Empyema, Pleural/virology , Epstein-Barr Virus Infections/pathology , Humans , Inflammation/immunology , Inflammation/pathology , Inflammation/virology , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/virology , Male , Mice , Mice, Inbred BALB C , Receptors, CCR4/biosynthesis , Receptors, CCR4/immunologyABSTRACT
Chemokines have crucial roles in organ development and orchestration of leukocyte migration. The chemokine CCL22 is expressed constitutively at high levels in the lymph node, but the functional significance of this expression is so far unknown. Studying a newly established CCL22-deficient mouse, we demonstrate that CCL22 expression by dendritic cells (DCs) promotes the formation of cell-cell contacts and interaction with regulatory T cells (T reg) through their CCR4 receptor. Vaccination of CCL22-deficient mice led to excessive T cell responses that were also observed when wild-type mice were vaccinated using CCL22-deficient DCs. Tumor-bearing mice with CCL22 deficiency showed prolonged survival upon vaccination, and further, CCL22-deficient mice had increased susceptibility to inflammatory disease. In conclusion, we identify the CCL22-CCR4 axis as an immune checkpoint that is crucial for the control of T cell immunity.
Subject(s)
Bone Marrow Cells/immunology , Cell Communication/immunology , Chemokine CCL22/immunology , Dendritic Cells/immunology , Lymph Nodes/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Cell Line, Tumor , Cell Movement , Chemokine CCL22/genetics , HEK293 Cells , Humans , Lymph Nodes/cytology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Receptors, CCR4/metabolism , Transplantation, HomologousSubject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Macrophages/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Hepatocellular/immunology , Chemokine CCL22/immunology , Female , Humans , Liver Neoplasms/immunology , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Middle Aged , Neoplasm Invasiveness/immunology , Neoplasm Metastasis/immunology , Young AdultABSTRACT
Macrophages (MΦs) are critical regulators of immune response and serve as a link between innate and acquired immunity. The precise mechanism of involvement of tissue-resident MΦs in the pathogenesis of autoimmune diseases is not clear. Here, using a murine model for Sjögren's syndrome (SS), we investigated the role of tissue-resident MΦs in the onset and development of autoimmunity. Two unique populations of CD11bhigh and CD11blow resident MΦs were observed in the target tissue of the SS model. Comprehensive gene expression analysis of chemokines revealed effective production of CCL22 by the CD11bhigh MΦs. CCL22 upregulated the migratory activity of CD4+ T cells by increasing CCR4, a receptor of CCL22, on T cells in the SS model. In addition, CCL22 enhanced IFN-γ production of T cells of the SS model, thereby suggesting that CCL22 may impair the local immune tolerance in the target organ of the SS model. Moreover, administration of anti-CCL22 antibody suppressed autoimmune lesions in the SS model. Finally, histopathological analysis revealed numerous CCL22-producing MΦs in the minor salivary gland tissue specimens of the SS patients. CCL22-producing tissue-resident MΦs may control autoimmune lesions by enhancing T cell response in the SS model. These results suggest that specific chemokines and their receptors may serve as novel therapeutic or diagnostic targets for SS.
Subject(s)
Chemokine CCL22/metabolism , Lacrimal Apparatus/pathology , Macrophages/immunology , Salivary Glands/pathology , Sjogren's Syndrome/immunology , T-Lymphocytes/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Autoimmunity , Cells, Cultured , Chemokine CCL22/immunology , Disease Models, Animal , Female , Humans , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , ThymectomyABSTRACT
Triple-negative breast cancer (TNBC) is particularly aggressive, with enhanced incidence of tumor relapse, resistance to chemotherapy, and metastases. As the mechanistic basis for this aggressive phenotype is unclear, treatment options are limited. Here, we showed an increased population of myeloid-derived immunosuppressor cells (MDSCs) in TNBC patients compared with non-TNBC patients. We found that high levels of the transcription factor ΔNp63 correlate with an increased number of MDSCs in basal TNBC patients, and that ΔNp63 promotes tumor growth, progression, and metastasis in human and mouse TNBC cells. Furthermore, we showed that MDSC recruitment to the primary tumor and metastatic sites occurs via direct ΔNp63-dependent activation of the chemokines CXCL2 and CCL22. CXCR2/CCR4 inhibitors reduced MDSC recruitment, angiogenesis, and metastasis, highlighting a novel treatment option for this subset of TNBC patients. Finally, we found that MDSCs secrete prometastatic factors such as MMP9 and chitinase 3-like 1 to promote TNBC cancer stem cell function, thereby identifying a nonimmunologic role for MDSCs in promoting TNBC progression. These findings identify a unique crosstalk between ΔNp63+ TNBC cells and MDSCs that promotes tumor progression and metastasis, which could be exploited in future combined immunotherapy/chemotherapy strategies for TNBC patients.
Subject(s)
Myeloid-Derived Suppressor Cells/immunology , Neoplastic Stem Cells/immunology , Transcription Factors/immunology , Triple Negative Breast Neoplasms/immunology , Tumor Suppressor Proteins/immunology , Animals , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Chemokine CXCL2/genetics , Chemokine CXCL2/immunology , Chitinase-3-Like Protein 1/genetics , Chitinase-3-Like Protein 1/immunology , Female , Humans , MCF-7 Cells , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/immunology , Mice , Mice, Inbred BALB C , Mice, Nude , Myeloid-Derived Suppressor Cells/pathology , Neoplasm Metastasis , Neoplastic Stem Cells/pathology , Receptors, CCR4/genetics , Receptors, CCR4/immunology , Receptors, CXCR4/genetics , Receptors, CXCR4/immunology , Transcription Factors/genetics , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology , Triple Negative Breast Neoplasms/therapy , Tumor Suppressor Proteins/geneticsABSTRACT
Eosinophil infiltration, a hallmark of allergic asthma, is essential for type 2 immune responses. How the initial eosinophil recruitment is regulated by lung dendritic cell (DC) subsets during the memory stage after allergen challenge is unclear. Here, we show that the initial eosinophil infiltration is dependent on lung cDC1s, which require nitric oxide (NO) produced by inducible NO synthase from lung CD24-CD11b+ DC2s for inducing CCL17 and CCL22 to attract eosinophils. During late phase responses after allergen challenge, lung CD24+ cDC2s inhibit eosinophil recruitment through secretion of TGF-ß1, which impairs the expression of CCL17 and CCL22. Our data suggest that different lung antigen-presenting cells modulate lung cDC1-mediated eosinophil recruitment dynamically, through secreting distinct soluble factors during the memory stage of chronic asthma after allergen challenge in the mouse.
Subject(s)
Asthma/immunology , Dendritic Cells/immunology , Eosinophils/immunology , Allergens/immunology , Animals , Chemokine CCL17/immunology , Chemokine CCL17/metabolism , Chemokine CCL22/immunology , Chemokine CCL22/metabolism , Chronic Disease , Dendritic Cells/metabolism , Disease Models, Animal , Female , Humans , Lung/cytology , Lung/immunology , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Papain/immunology , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/metabolismABSTRACT
Two different vasoactive intestinal peptide (VIP) amphiphiles have been formulated which readily form micelles of varying shapes. Interestingly, VIP micelle structure has been found to directly correlate to anti-inflammatory behavior providing evidence that these biomaterials can serve as a promising new therapeutic modality.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Dendritic Cells/drug effects , Immunologic Factors/pharmacology , Macrophages/drug effects , T-Lymphocytes, Regulatory/drug effects , Vasoactive Intestinal Peptide/pharmacology , Animals , B7-2 Antigen/genetics , B7-2 Antigen/immunology , Cells, Cultured , Chemokine CCL22/genetics , Chemokine CCL22/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , Gene Expression , Humans , Lipopolysaccharides/antagonists & inhibitors , Lipopolysaccharides/pharmacology , Macrophages/cytology , Macrophages/immunology , Mice , Micelles , Protein Structure, Secondary , Surface-Active Agents/chemistry , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolismABSTRACT
The existing therapies of IgA nephropathy are unsatisfying. Acteoside, the main component of Rehmannia glutinosa with anti-inflammatory and anti-immune effects, can improve urinary protein excretion and immune disorder. Th22 cell is involved in IgA nephropathy progression. This study was determined to explore the effect of acteoside on mesangial injury underlying Th22 cell disorder in IgA nephropathy. Serum Th22 cells and urine total protein of patients with IgA nephropathy were measured before and after six months treatment of Rehmannia glutinosa acteoside or valsartan. Chemotactic assay and co-culture assay were performed to investigate the effect of acteoside on Th22 cell chemotaxis and differentiation. The expression of CCL20, CCL22 and CCL27 were analyzed. To explore the effect of acteoside on mesangial cell injury induced by inflammation, IL-1, IL-6, TNF-α and TGF-ß1 were tested. Results showed that the proteinuria and Th22 lymphocytosis of patients with IgA nephropathy significantly improved after combination treatment of Rehmannia glutinosa acteoside and valsartan, compared with valsartan monotherapy. In vitro study further demonstrated that acteoside inhibit Th22 cell chemotaxis by suppressing the production of Th22 cell attractive chemokines, i.e., CCL20, CCL22 and CCL27. In addition, acteoside inhibited the Th22 cell proliferation. Co-culture assay proved that acteoside could relieve the overexpression of pro-inflammatory cytokines, and prevent the synthesis of TGF-ß1. TGF-ß1 level in mesangial cells was positively correlated with the Th22 cell. This research demonstrated that acteoside can alleviate mesangial cell inflammatory injury by modulating Th22 lymphocytes chemotaxis and proliferation.
Subject(s)
Glomerulonephritis, IGA/drug therapy , Glucosides/pharmacology , Immunosuppressive Agents/pharmacology , Mesangial Cells/drug effects , Phenols/pharmacology , T-Lymphocytes, Helper-Inducer/drug effects , Adult , Biopsy , Cell Line , Cell Proliferation/drug effects , Chemokine CCL20/immunology , Chemokine CCL20/metabolism , Chemokine CCL22/immunology , Chemokine CCL22/metabolism , Chemokine CCL27/immunology , Chemokine CCL27/metabolism , Chemotaxis/drug effects , Chemotaxis/immunology , Coculture Techniques , Disease Progression , Drug Therapy, Combination/methods , Female , Glomerulonephritis, IGA/immunology , Glomerulonephritis, IGA/pathology , Glucosides/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Male , Mesangial Cells/immunology , Mesangial Cells/pathology , Middle Aged , Phenols/therapeutic use , Proteinuria/drug therapy , Rehmannia/chemistry , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Helper-Inducer/metabolism , Transforming Growth Factor beta1/immunology , Transforming Growth Factor beta1/metabolism , Treatment Outcome , Valsartan/therapeutic use , Young AdultABSTRACT
Few studies have addressed the mother-to-child transmission of Th2 immunity and the impact on the development of atopic diseases in early childhood. We investigated 186 children who were followed-up regularly for 4 years in a birth cohort study. The levels of Th2 related chemokine (C-C motif) ligand 17 (CCL17) and CCL22 were quantified in cord blood and at 1.5 years-of-age using multiplex Luminex kits. The levels of 125 pairs of CCL17 and CCL22 chemokines from birth to 1.5 years were recorded in this study. Using K-means clustering, only the declining trend of CCL22 levels was separately clustered (cluster A, n = 51; cluster B, n = 46; cluster C, n = 28). Mothers of children with higher CCL22 chemokine levels at birth were significantly more likely to display Dermatophagoides pteronyssinus sensitization. A lower CCL22 level at birth with a slight rise during infancy was associated with higher prevalence of mite sensitization and a higher risk of asthma at 3 years-of-age (P = 0.014). In conclusion, low mother-to-child Th2-associated chemokine CCL22 levels appear to be inversely related to mite sensitization and the risk of asthma development in early childhood.
Subject(s)
Asthma/etiology , Chemokine CCL17/blood , Chemokine CCL22/blood , Dermatophagoides pteronyssinus/immunology , Animals , Asthma/blood , Asthma/immunology , Chemokine CCL17/immunology , Chemokine CCL22/immunology , Child, Preschool , Dermatitis, Atopic/blood , Dermatitis, Atopic/etiology , Dermatitis, Atopic/immunology , Female , Follow-Up Studies , Humans , Immunoglobulin E/blood , Immunoglobulin E/immunology , Infant , Male , Risk Factors , Th2 Cells/immunologyABSTRACT
BACKGROUND: Tonsillitis can promote the progression of IgA nephropathy (IgAN) by aggravating immunopathologic response. Th22 cell disorder is involved in the pathogenesis of IgAN with tonsillitis. This study was determined to explore the possible mechanism of IgAN with tonsillitis underlying Th22 cell chemotaxis response to the effect of CCL20, CCL22, and CCL27. METHODS: This research was conducted on 65 subjects including 16 healthy controls (HC group), 5 patients with renal carcinoma (HTC group) and 44 patients with IgAN between 2015 and 2016. According to clinical symptoms and results of throat swab culture, patients with IgAN were divided into two groups: IgAN with tonsillitis (IgAN + tonsillitis, n = 14) and IgAN patients without tonsillitis (IgAN, n = 30). Distribution of Th22 cells in IgAN patients was determined. The expression of CCL20, CCL22, and CCL27 in both peripheral blood and kidneys of IgAN patients was investigated. Severity of pathological lesions in IgAN patients was analyzed. Coculture assay and transwell assay were performed to explore the impacts of human mesangial cells (HMC) on Th22 cell chemotaxis and Th22 cell local accumulation under hemolytic streptococcus (HS) infection. RESULTS: Th22 cell percentages in IgAN patients increased compared with healthy controls. This increased Th22 cell percentage was positively correlated with the renal lesions of IgAN patients. Correspondingly, the expression of CCL20, CCL22, and CCL27 in renal tissue increased in IgAN patients. Tonsillitis exacerbated these overrepresentations of Th22 cells and chemokines. It was found that HMC could produce CCL20, CCL22, and CCL27. The supernatant of HMC was chemotactic for Th22 cells. This activity of HMC was stimulated by HS infection, whereas treatment of anti-CCL20, anti-CCL22, and anti-CCL27 antibodies partly blocked this chemoattractant effect of HMC. CONCLUSIONS: Tonsil infection may aggravate the renal pathological lesions of IgAN by exacerbating Th22 cell accumulation. Our data suggested a collaboration between HMC and Th22 cells in IgAN with tonsillitis underlying the effects of CCL20, CCL22, and CCL27.
Subject(s)
Acute Kidney Injury/etiology , Chemokine CCL22/immunology , Glomerulonephritis, IGA/complications , Glomerulonephritis, IGA/pathology , Th2 Cells/immunology , Tonsillitis/complications , Acute Kidney Injury/pathology , Acute Kidney Injury/physiopathology , Adult , Analysis of Variance , Biopsy, Needle , Case-Control Studies , Cells, Cultured , Chemokine CCL22/metabolism , Chemotaxis/immunology , Coculture Techniques , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Glomerulonephritis, IGA/diagnosis , Humans , Immunohistochemistry , Male , Statistics, Nonparametric , Th2 Cells/metabolism , Tonsillitis/diagnosisABSTRACT
Objectives: Targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway holds great potential in the treatment of inflammatory diseases. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody, has demonstrated clinical efficacy in RA. Our current study aimed to elucidate mechanisms of action and identify peripheral biomarkers associated with therapeutic responses of GM-CSF antagonism in RA. Methods: A 24-week placebo (PBO)-controlled trial was conducted in 305 RA patients who received mavrilimumab (30, 100 or 150 mg) or PBO once every 2 weeks. Serum biomarkers and whole blood gene expression profiles were measured by protein immunoassay and whole genome microarray. Results: Mavrilimumab treatment induced significant down-regulation of type IV collagen formation marker (P4NP 7S), macrophage-derived chemokine (CCL22), IL-2 receptor α and IL-6 compared with PBO. Both early and sustained reduction of P4NP 7S was associated with clinical response to 150 mg mavrilimumab treatment. Gene expression analyses demonstrated reduced expression of transcripts enriched in macrophage and IL-22/IL-17 signalling pathways after GM-CSF blockade therapy. Myeloid and T cell-associated transcripts were suppressed in mavrilimumab-treated ACR20 responders but not non-responders. While CCL22 and IL-6 down-regulation may reflect a direct effect of GM-CSFR blockade on the production of pro-inflammatory mediators by myeloid cells, the suppression of IL-2 receptor α and IL-17/IL-22 associated transcripts suggests an indirect suppressive effect of mavrilimumab on T cell activation. Conclusion: Our results demonstrated association of peripheral biomarker changes with therapeutic response to mavrilimumab in RA patients. The sustained efficacy of mavrilimumab in RA may result from both direct effects on myeloid cells and indirect effects on T cell activation after GM-CSFR blockade.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Arthritis, Rheumatoid/drug therapy , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Adult , Antibodies, Monoclonal, Humanized , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , Chemokine CCL22/immunology , Collagen Type IV/metabolism , Double-Blind Method , Down-Regulation , Female , Humans , Interleukin-17/genetics , Interleukin-17/immunology , Interleukin-2 Receptor alpha Subunit/immunology , Interleukin-6/immunology , Interleukins/genetics , Interleukins/immunology , Macrophages/immunology , Male , Middle Aged , Myeloid Cells/immunology , RNA, Messenger/metabolism , Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors , Signal Transduction , T-Lymphocytes/immunology , Transcriptome , Interleukin-22ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). It affects more than two million people worldwide, mainly young adults, and may lead to progressive neurological disability. Chemokines and their receptors have been shown to play critical roles in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), a murine disease model induced by active immunization with myelin proteins or transfer of encephalitogenic CD4⺠T cells that recapitulates clinical and neuropathological features of MS. Chemokine ligand-receptor interactions orchestrate leukocyte trafficking and influence multiple pathophysiological cellular processes, including antigen presentation and cytokine production by dendritic cells (DCs). The C-C class chemokines 17 (CCL17) and 22 (CCL22) and their C-C chemokine receptor 4 (CCR4) have been shown to play an important role in homeostasis and inflammatory responses. Here, we provide an overview of the involvement of CCR4 and its ligands in CNS autoimmunity. We review key clinical studies of MS together with experimental studies in animals that have demonstrated functional roles of CCR4, CCL17, and CCL22 in EAE pathogenesis. Finally, we discuss the therapeutic potential of newly developed CCR4 antagonists and a humanized anti-CCR4 antibody for treatment of MS.
Subject(s)
Autoimmune Diseases of the Nervous System/immunology , Autoimmunity , Chemokine CCL17/immunology , Chemokine CCL22/immunology , Receptors, CCR4/immunology , Animals , Autoimmune Diseases of the Nervous System/drug therapy , Autoimmune Diseases of the Nervous System/pathology , Autoimmunity/immunology , Central Nervous System/drug effects , Central Nervous System/immunology , Central Nervous System/pathology , Chemokine CCL17/analysis , Chemokine CCL22/analysis , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/pathology , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Humans , Molecular Targeted Therapy/methods , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Receptors, CCR4/analysisABSTRACT
Myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs) arise from common progenitors. Tumor-derived factors redirect differentiation from immune-promoting DCs to tolerogenic MDSCs, an immunological hallmark of cancer. Indeed, in vitro differentiation of DCs from human primary monocytes results in the generation of MDSCs under tumor-associated conditions (PGE2 or tumor cell-conditioned media). Comparison of MDSC and DC DNA methylomes now reveals extensive demethylation with specific gains of DNA methylation and repression of immunogenic-associated genes occurring in MDSCs specifically, concomitant with increased DNA methyltransferase 3A (DNMT3A) levels. DNMT3A downregulation erases MDSC-specific hypermethylation, and it abolishes their immunosuppressive capacity. Primary MDSCs isolated from ovarian cancer patients display a similar hypermethylation signature in connection with PGE2-dependent DNMT3A overexpression. Our study links PGE2- and DNMT3A-dependent hypermethylation with immunosuppressive MDSC functions, providing a promising target for therapeutic intervention.